Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Preparation of a Nanoemulsion Containing Active Ingredients of Cannabis Extract and Its Application for Glioblastoma: In Vitro and in Vivo Studies Publisher Pubmed



Mobaleghol Eslam H1 ; Hataminia F1 ; Esmaeili F1 ; Salami SA2, 5 ; Ghanbari H1, 3 ; Amani A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Biotechnology, Faculty of Agricultural Science and Engineering, University of Tehran, Karaj, Iran
  3. 3. Medical Biomaterials Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran
  5. 5. Industrial and Medical Cannabis Research Institute (IMCRI), Tehran, Iran

Source: BMC Pharmacology and Toxicology Published:2024


Abstract

Recently, the anti-tumor effects of cannabis extract on various cancers have attracted the attention of researchers. Here, we report a nanoemulsion (NE) composition designed to enhance the delivery of two active components in cannabis extracts (∆9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)) in an animal model of glioblastoma. The efficacy of the NE containing the two drugs (NED) was compared with the bulk drugs and carrier (NE without the drugs) using the C6 tumor model in rats. Hemocompatibility factors (RBC, MCV, MCH, MCHC, RDW, PPP, PT and PTT) were studied to determine the potential in vivo toxicity of NED. The optimized NED with mean ± SD diameter 29 ± 6 nm was obtained. It was shown that by administering the drugs in the form of NED, the hemocompatibility increased. Cytotoxicity studies indicated that the NE without the active components (i.e. mixture of surfactants and oil) was the most cytotoxic group, while the bulk group had no toxicity. From the in vivo MRI and survival studies, the NED group had maximum efficacy (with ~4 times smaller tumor volume on day 7 of treatment, compared with the control. Also, survival time of the control, bulk drug, NE and NED were 9, 4, 12.5 and 51 days, respectively) with no important adverse effects. In conclusion, the NE containing cannabis extract could be introduced as an effective treatment in reducing brain glioblastoma tumor progression. Graphical abstract: (Figure presented.) © The Author(s) 2024.
Related Docs
1. A Review on the Use of Essential Oil-Based Nanoformulations in Control of Mosquitoes, Biointerface Research in Applied Chemistry (2021)
2. Lemon Essential Oil Nanoemulsion Containing Ascorbyl Tetraisopalmitate: Investigating the Relationship Between Surfactant Hlb and Size, Nanomedicine Research Journal (2025)
3. Therapeutic Attributes of Endocannabinoid System Against Neuro-Inflammatory Autoimmune Disorders, Molecules (2021)
4. Lipidomics-Driven Drug Discovery and Delivery Strategies in Glioblastoma, Biochimica et Biophysica Acta - Molecular Basis of Disease (2025)
5. Anti-Rheumatic Activity of Topical Nanoemulsion Containing Bee Venom in Rats, European Journal of Pharmaceutics and Biopharmaceutics (2022)
6. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms, Vaccines (2022)
7. The Role of Cell Membrane-Coated Nanoparticles As a Novel Treatment Approach in Glioblastoma, Frontiers in Molecular Biosciences (2023)
8. The Endocannabinoid System, a New Gatekeeper in the Pharmacology of Human Hepatocellular Carcinoma, Environmental Research (2023)
Experts (# of related papers)
Nima Rezaei (1)
Seyedeh Elahe Mousavi (1)